Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain

V. J. Hruby, R. S. Agnes, P. Davis, S. W. Ma, Y. S. Lee, T. W. Vanderah, J. Lai, F. Porreca

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Disease states such as neuropathic pain offer special challenges in drug design due to the system changes which accompany these diseases. In this manuscript we provide an example of a new approach to drug design in which we have modified a potent and selective peptide ligand for the CCK-2 receptor to a peptide which has potent agonist binding affinity and bioactivity at delta and mu opioid receptors, and simultaneous antagonist activity at CCK receptors. De novo design based on the concept of overlapping pharmacophores was a central hypothesis of this design, and led to compounds such as H-Tyr-DPhe-Gly-DTrp-NMeNle-Asp-Phe-NH2 (i.e., RSA 601) which have the designed properties.

Original languageEnglish (US)
Pages (from-to)699-704
Number of pages6
JournalLife Sciences
Volume73
Issue number6
DOIs
StatePublished - Jun 27 2003

Keywords

  • Cholecystokinin antagonists
  • Neuropathic pain
  • Opioid agonists
  • Peptide drug design

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain'. Together they form a unique fingerprint.

  • Cite this